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ABSTRACT
Objective: The present investigation for the first time evaluated the in vitro fibrinolytic and thrombolytic activities of crude extracts from 
Eutyphoeus  gammiei, native, large size earthworm of Tripura, Northeast, India. The present study was designed to evaluate the therapeutic use of the 
organism E.  gammiei as a source of fibrinolytic and thrombolytic agent(s).
Methods: The fibrinolytic activity was studied using by fibrin plate and zymography assays. Thrombolytic assay was carried out according to Prasad 
et al. (2006) using whole blood.
Results: The results obtained clearly indicated E. gammiei as a potential source of fibrinolytic and thrombolytic agents. Both in fibrin plate assay 
and thrombolytic assay with whole blood, E. gammiei crude homogenate showed similar and close results in respect to that of streptokinase. Fibrin 
zymography also showed antifibrinolytic activity with producing clear bands. Dose and time dependency also is evident from the results.
Conclusion: The results of the present study conclude that the studied earthworm species E. gammiei possessed profound fibrinolytic and thrombolytic 
activity on human blood and E. gammiei might prove to be useful alternative source for the development of new drugs for treatments involving blood 
coagulation and fibrinolysis.
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INTRODUCTION
Thrombolytic disorders including cerebral stroke and myocardial 
infarctions have become a serious concern all over the world. Commonly 
used fibrinolytic agents that dissolve clots are urokinase, streptokinase 
(ST), and tissue plasminogen activator. These are not specific for fibrin 
and have adverse and dangerous side effect including severe bleeding 
and thereby blood loss which may result in death  [1,2]. On the other 
hand, earthworm fibrinolytic enzyme, also known as Lumbrokinase 
(LK), is very specific to fibrin and it does not cause excessive 
bleeding  [1,2]. Lumbrokinase has also shown promise for use in 
lowering whole blood viscosity and reducing platelets aggregation  [3,4]. 
Earthworm fibrinolytic enzymes can be transported into the blood 
through the intestinal epithelium, and the enzyme works after oral 
administration  [5]. The most common source of earthworm fibrinolytic 
enzyme is Lumbricus rubellus, Eisenia foetida, and Paritima sp. 
Isoenzymes constituents of each earthworm may vary depending on the 
species and living environment which may lead to differences in their 
activities [6]. Approximately 4400 different species have been identified 
worldwide. According to Julka et al. [7], of the 12 families of earthworms, 
the subcontinent has representative genera species form 9 families. In 
the year 2009 Julka et al. [8] reported that Indian earthworm fauna 
comprises about 590 species. Altough there are many reports regarding 
earthworm fibrinolytic enzymes from China, Japan, and other Far-East 
Countries, there are very few reports from India and almost no report 
from North East India. This present study intends to explore for the first 
time fibrinolytic and thrombolytic activity of Eutyphoeus gammiei an 
earthworm collected from Tripura, Northeast India.
METHODS
Sample collection and identification
Adult earthworm E. gammiei was collected by hand sorting and 
digging method by spade from Agartala, Tripura at early morning. 
The sample was first identified by Prof. P S Choudhuri, Earthworm 
Research Laboratory, Department of Zoology, Tripura University. The 
sample specimen was also submitted to ZSI, Kolkata, for authentication 
(voucher number- An 5649/1) (Fig. 1).
Collection site
The sample was collected from Agartala (Shibnagar), Tripura West, 
India. The site was demarcated using global positioning system 
(Latitude: N=23.82914° and Longitude: E=091.29485°) (Fig. 2).
Preparation of earthworm homogenate
Earthworm E. gammiei was first washed with running tap water and 
then fed with wet blotting paper for 18–20 h to clear their gut. The gut 
cleared worms were again washed with distilled water. 20% gut cleared 
earthworm homogenate was prepared in 0.2M phosphate buffered 
saline (PBS), pH-7.2. Homogenate was filter sterilized before use.
Determination of protein concentration
Protein concentration was determined following Lowry’s et al. 
method  [9].
Fibrinogen degradation assay
Fibrinolytic activity of the extract was carried out by the fibrin plate 
method [10]. Fibrin plate was prepared by mixing 6 ml of 0.6% bovine 
plasma fibrinogen and 6 ml of 1.5% agarose containing 10 NIH units 
of bovine plasma thrombin. 0.1 M phosphate buffer, pH 7.4 was used 
throughout the experiment. The prepared solution was quickly poured 
into a 90 mm diameter Petri plates and allowed to stand for 1 h at room 
temperature and labeled as fibrin plate. The earthworm was applied 
directly into a small pore created in the Petri plate containing artificial 
fibrin. ST was used as a positive control, and PBS served as negative 
controls. The Petri plate was incubated at 37°C for various lengths of 
time. Fibrinolytic activity was determined by examining the formation 
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of the zone of lysis in the form of a clear hollow in the fibrin plate. 
Fibrinolytic activity was assessed by measuring the lysis zone. The 
procedure was repeated 4–5 times.
Sodium dodecyl sulfate-poly acryl amide gel electrophoresis (SDS 
PAGE)
SDS PAGE was done to determine the purity and molecular weight of 
the enzyme, as described by Laemmli [11] using a 5% (w/v) stacking 
and a 10% (w/v) separating gels. The molecular weight of the enzyme 
was estimated using a low molecular weight calibration kit (Bio-Rad) 
as a marker.
Fibrin zymography assay
Fibrin zymography was performed as described previously [12] bovine 
fibrinogen (0.12% w/v, Sigma) dissolved in 20 mM sodium phosphate 
buffer (pH 7.4) and 100 µl of bovine thrombin (10NIH unit ml Sigma) 
were copolymerized with 12% (w/v) acrylamide. 0.32% (w/v) bis 
acrylamide and 375 mM Tris/HCL (pH 8.8) to make the fibrin gel as the 
running gel. Then 5% w/v0 acrylamide, 0.11% (w/v) bis acrylamide, 
and 330 nM Tris/HCL (pH 6.8) (no fibrinogen) were used for the 
stacking gel, which was poured into a mini-gel cast (Bio-Rad). The 
samples for analysis were prepared by diluting the culture supernatant 
5-fold with zymogram sample buffer (0.5M Tris/HCL, pH 6.8, 10% SDS, 
20% SDS, 20% glycerol, and 05.% Bromophenol Blue) [13]. After the 
prepared samples (10 µl) were loaded into the wells, electrophoresis 
(Laemmli, 1970) was carried out in the cold room (4°C) at a constant 
12mA. After electrophoresis, the gel was incubated for 30 min at 
room temperature on a rotary shaker in 50 nM Tris/Cl (pH 7.4) which 
contains 2.5% Triton X-100. The gel was washed with distilled water to 
remove Triton X-100, and then incubated in Zymogram reaction buffer 
(30 mM Tris/HCL, pH 7.4, 200 mM Nacl, 10 mM CaCl2, and 0.02% Brij-
35) at 37°C for 12 h. The gel was stained with Coomassie blue for 1 h 
and then distained. The digested bands were visualized as the non-
stained regions of the fibrin gel.
Thrombolytic assay
Thrombolytic assay was carried out according to Prasad et al., [14]. 
Venous blood was drawn from healthy volunteers after taking informed 
consent (n=3). 0.5 ml venous blood was put into pre-weighed sterile 
microcentrifuge tubes and was incubated at 37°C for 60 min. After that, 
serum was removed from the blood clot. Phosphate buffer (20 mM), 
as blank, and 100 µl of homogenate (0.5 mg/ml) in Phosphate buffer 
(20 mM) was added separately to the clot and incubated at 37°C for 
2 h, 6 h, 12 h, and 24 h. Fluids were removed from the remaining clots, 
and the tubes were weighed. Thrombolytic activity was calculated by 
comparing the initial weight of blood clot to that of lysed blood clot. ST 
was used as positive control.
RESULTS
Result obtained in the form of clear zone in fibrin plate is presented in 
Figs. 3 and 5. The diameter of the circles proportionately increased with 
the increase of incubation time and amount of homogenate (Fig. 5). 
Clear zone appeared around test and positive control (well no-II, III, 
IV, V, VI, and VII) whereas, in negative control (well no-I) containing 
only PBS, no clear zone appeared. Mouth and anus parts of the whole 
organism showed no activity (Fig. 3.).
When the activity of the homogenate was compared with that of 
positive control (ST), at the given protein concentration (0.5 mg/ml), 
the response of the homogenate was found to be very close to that 
of ST. Results clearly indicated that E. gammiei possessed fibrinolytic 
activity which was very similar to ST activity. In SDS PAGE, prominent 
bands ranging from 44 KD to 20 KD were observed, Fig. 6. To confirm 
the fibrinolytic activity, zymography with fibrin was performed. In 
zymogram two bands, though diffused, were observed, indicating the 
presence of isozymes (Fig. 7).
Thrombolytic activity
Visual blood clot lysis is shown in Fig. 8. Negative control containing 
×1 PBS was mixed to blood clot, no obvious lysis was observed. 
Both standard ST (positive control) and homogenate increased the 
percentage of clot lysis in time-dependent manner. Highest clot lysis 
was observed with the addition of 100 µl of standard ST containing 
Fig. 2: Site of sample collection ([a] map of India and [b] map of Tripura showing the exact location of the site of collection)
ba
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3.7 International Unit/µl and homogenate containing 0.5 mg/ml, 
respectively.
DISCUSSION
Fibrinolytic enzymes dissolve fibrin, the main component of blood 
clots. Accumulation of fibrin in the blood vessels results in thrombosis, 
leading to myocardial infarction, and other heart diseases [15,16] 
which are the leading causes of death throughout the world. 
Fibrinolytic enzyme has been successfully identified from various 
sources [17]. Fibrinolytic enzymes and thrombolytic agents currently 
available for clinical use, such as ST, urokinase, pro-urokinase, 
reteplase, and alteplase suffer significant unintended physiological 
Fig. 3: Different parts of Eutyphoeus gammiei exhibit strong fibrinolysis. The sections were applied directly to the Petri dish plate 
containing artificial fibrin and incubated at 37°C overnight. Phosphate buffered saline was applied in the center well of the plate as 
negative controls. Bigger lysis halos (2,3,4,5) indicated higher fibrinolytic activity regions
Fig. 4: Graphical representation of the fibrinolytic activity of 
different sections of Eutyphoeus gammiei
Fig. 5: Effect of homogenate of Eutyphoeus gammiei on fibrin plate 
at different incubation time interval. EGH: Eutyphoeus gammiei 
homogenate, ST: Streptokinase
Fig. 6: Sodium dodecyl sulfate-poly acrylamide gel 
electrophoresis (10%) of homogenate of earthworm Eutyphoeus 
gammiei M: Pre-stained protein marker (Biored), H: Homogenate 
of Eutyphoeus gammiei
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effects such as excessive bleeding, short plasma half-life, limited fibrin 
specificity, and large therapeutic dose [18]. Therefore, search for less 
expensive and safer fibrinolytic enzymes and thrombolytic agents 
from other sources are still an urgent issue [19]. The scientists are 
always in search of biopotential compounds from natural sources for 
the treatment of various diseases. More and more researchers have 
focused on the analysis of bioactive proteins in earthworm coelomic 
fluid and glycolipoprotein powder [20]. The earthworm protease 
functions in the fibrinolysis and plasminogen activation have found to 
be associated with less side effects in comparison to that of urokinase, 
ST recombinant tissue-type plasminogen activator, etc., [21]. The 
protease during orally/administered experiments both in animals 
and clinical shows significant efficacy. The protease has been found 
to be stable during long-term storage at room temperature [22]. 
However, because of the various living environment, different species 
of earthworms have different resultant isozymes [6]. Not many 
species of earthworms have been studied for fibrinolytic enzymes 
across the world.
In this study, E. gammiei an earthworm species native to North East 
India has been explored for fibrinolytic and thrombolytic potentiality. 
The results obtained (Table 1 and Figs. 4 and 5) clearly indicated 
E.  gammiei as a potential source of fibrinolytic and thrombolytic 
agents. Both in fibrin plate assay and thrombolytic assay with whole 
blood, E  gammiei crude homogenate showed similar and close results 
in respect to that of the standard drug in use ST. Fibrin zymography 
also showed antifibrinolytic activity with producing clear bands 
(Figs. 6 and 7). Dose and time dependency also was evident from 
the results. Further purification and characterization can lead to the 
clinical use of these enzymes. Therefore, along with other species, so 
far studied, E. gammiei collected from Northeastern part of India can 
also be a potential new source of fibrinolytic enzyme for clinical use.
CONCLUSION
The study suggested that crude extracts from earthworm of E. gammiei 
might prove to be useful alternative source for the development of 
new drugs for treatments involving blood clot and fibrinolysis. Further 
studies can now be designed to characterize and identify the protein of 
the E. gammiei extract involved in the fibrinolytic activity.
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experiment as well as preparation of the manuscript.Fig. 8: Thrombolytic activity of homogenate of Eutyphoeus 
gammiei on human blood clot at a different time interval
Fig. 7: Fibrin zymography with Eutyphoeus gammiei homogenate
Table 1: Data for comparative fibrinolytic effects of homogenate of Eutyphoeus gammiei on fibrin plate at different incubation period
EGH: Eutyphoeus gammiei 
homogenate,  
ST: Streptokinase
0H 2H 6H 12H 18H 24H
EGH 20 µl (10 µg) 0 11.66±0.33 15±0.57 18.66±0.33 24.66±0.33 25.33±0.33
ST 20 µl 0 12.33±0.33 16.66±0.33 19±0.57 24.66±1.15 27.00±1.00
EGH 40 µl (20 µg) 0 12.66±0.33 16.66±0.66 20.33±0.33 27.00±0 28.66±0.66
ST 40 µl 0 12.66±0.33 18.33±0.88 23.33±0.88 28.00±1.00 28.66±0.66
EGH 60 µl (30 µg) 0 13.66±0.33 19.33±0.67 24.00±0.57 29.33±2.85 29.66±0.66
ST 60 µl 0 14.66±0.33 20.00±1.15 24.66±0.88 29.33±0.66 30.66±0.66




Thrombolytic effect of 
Eutyphoeus gammiei after 
1 h
Thrombolytic effect of 
Eutyphoeus gammiei after 
2 h 
Thrombolytic effect of 
Eutyphoeus gammiei after 
6 h 
Thrombolytic effect of 
Eutyphoeus gammiei after 
12 h 
Control 0% 0% 0% 0%
Streptokinase 6±0.2 41.77±0.02 55.10±0.1 57.14±0.02
Homogenate 2±0.2 40.8±0.15 51.02±0.01 55.10±0.1
Table 2: Percentage of thrombolytic effect of Homogenate of Eutyphoeus gammiei
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